Navigation Links
AFRESA(R) Phase 3 Pulmonary Function Safety Data in Patients with Diabetes Presented at ADA
Date:6/6/2009

Two-year study presented at the American Diabetes Association's 69th Scientific Sessions shows investigational product comparable to standard insulin therapy in pulmonary function tests

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- AFRESA(R) (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin with changes in pulmonary function tests comparable to usual antidiabetic treatment, according to data presented today at the American Diabetes Association's 69th Scientific Sessions. Results from the prospective, multicenter, phase 3 study conducted over a two-year period showed no difference in mean change in forced expiratory volume in one second (FEV(1)) between those treated with AFRESA and those treated with standard insulin therapy.

"Current mealtime insulin therapies, while accepted as an effective means to control glucose levels, have several limitations," said Peter Richardson, Corporate Vice President and Chief Scientific Officer, MannKind Corporation. "Our encouraging findings indicate that AFRESA may be a promising new treatment option with less weight gain and lower risk of hypoglycemia compared with current mealtime insulin therapy."

AFRESA is a novel, ultra rapid acting mealtime insulin therapy with an action profile that mimics meal-related early insulin release. Based on an extensive phase 3 clinical program, a New Drug Application (NDA) has been accepted by the U.S. Food and Drug Administration (FDA) requesting approval to market AFRESA Inhalation Powder and the AFRESA Inhaler for use in adult patients with type 1 and type 2 diabetes mellitus for the treatment of hyperglycemia. AFRESA is conveniently administered by oral inhalation.

Diabetes, which affects 23.6 million people in the U.S., or 8 percent of the population, is characterized by the body's inability to properly regulate levels of blood glucose, or blood sugar. Insulin, a hormone
'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
2. PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
3. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
6. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
9. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
10. TNFerade(TM) Phase III Data Presented at ASCO
11. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... -- Stryker Corporation,s Orthopaedics Division, the Official Joint Replacement Products of ... of joint health to golf fans in its home state ... The Barclays.  The company,s fan destination – "The Stryker Mobility ... 17 th fairway at the Ridgewood Country Club in ... st .    At The Barclays, Stryker will ...
(Date:8/19/2014)... 19, 2014  SCILEX Pharmaceuticals, Inc., a company engaged ... for the treatment of pain, announced that it had formed ... Jeff Gudin , Dr. Charles Argoff , ... Vought . SCILEX Chief Executive Officer ... board would greatly assist in the development and commercialization ...
(Date:8/19/2014)... , August 19, 2014 ... ), a clinical-stage pharmaceutical company focused on the ... that the Intellectual Property Department of ... for its invention, titled "Methods and Compositions for ... Pharmaceuticals  Oramed Pharmaceuticals is a technology ...
Breaking Medicine Technology:Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 2Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 3Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 4Stryker, The Official Joint Replacement Products Of The PGA TOUR, Welcomes Golf Fans To Its Home State Of New Jersey For The Barclays 5SCILEX Pharmaceuticals Announces Scientific Advisory Board 2SCILEX Pharmaceuticals Announces Scientific Advisory Board 3SCILEX Pharmaceuticals Announces Scientific Advisory Board 4Oramed Granted Patent in Spain for Oral Administration of Insulin 2Oramed Granted Patent in Spain for Oral Administration of Insulin 3
... Feb. 9, 2012 /PRNewswire-Asia/ -- Winner Medical Group Inc. (Nasdaq: ... a leading China-based exporter and retailer of high-quality medical ... reported consolidated financial results for the first quarter of ... First Quarter of Fiscal 2012 Financial Highlights ...
... 9, 2012 Halozyme Therapeutics, Inc. (NASDAQ: HALO ... shares of its common stock pursuant to an effective shelf ... is the sole book-running manager of the offering, and Halozyme ... purchase up to an additional 1,020,000 shares of common stock. ...
Cached Medicine Technology:Winner Medical Reports First Quarter of Fiscal 2012 Results 2Winner Medical Reports First Quarter of Fiscal 2012 Results 3Winner Medical Reports First Quarter of Fiscal 2012 Results 4Winner Medical Reports First Quarter of Fiscal 2012 Results 5Winner Medical Reports First Quarter of Fiscal 2012 Results 6Winner Medical Reports First Quarter of Fiscal 2012 Results 7Winner Medical Reports First Quarter of Fiscal 2012 Results 8Winner Medical Reports First Quarter of Fiscal 2012 Results 9Winner Medical Reports First Quarter of Fiscal 2012 Results 10Winner Medical Reports First Quarter of Fiscal 2012 Results 11Winner Medical Reports First Quarter of Fiscal 2012 Results 12Winner Medical Reports First Quarter of Fiscal 2012 Results 13Winner Medical Reports First Quarter of Fiscal 2012 Results 14Winner Medical Reports First Quarter of Fiscal 2012 Results 15Winner Medical Reports First Quarter of Fiscal 2012 Results 16Winner Medical Reports First Quarter of Fiscal 2012 Results 17Winner Medical Reports First Quarter of Fiscal 2012 Results 18Halozyme Announces Proposed Public Offering of Common Stock 2Halozyme Announces Proposed Public Offering of Common Stock 3
(Date:8/20/2014)... Botanica Day Spa ... the new and popular stem cell line from ... and wrinkles and naturally repairs the skin. The ... new service by offering clients a complimentary dermaplaning ... facial. , Pevonia® continues to be a global ...
(Date:8/20/2014)... has been chosen by Plymouth University to be an ... April 2009 to raise awareness of, and funding for, ... brain tumour patients. , A range of events and ... the charity, and members of staff and students, as ... donate, fundraise and volunteer. The involvement of the wider ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 If old age ... a cure for it. With extensive research on HGH and ... ‘MetroMD’ claims to have perfected the art of rubbing off ... brand new younger look with their revolutionary anti-aging hormone therapy ... the 21st century fountain of youth, the MD of MetroMD, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 New Jersey’s ... needs of an estimated tens of thousands of patients ... new Bill A3525—a bill that would expand the list ... their own cannabis—earlier this summer by State Assemblywoman Linda ... medicinal quality marijuana is growing. , To help fill ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
Breaking Medicine News(10 mins):Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 2Health News:New Stem Cell Facial Unveiled at Botanica Day Spa 3Health News:Plymouth University chooses Brain Tumour Research as official charity 2Health News:MetroMD Offers Revolutionary Anti-aging Hormone Therapy in Hollywood Area 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3
... Nanophase Technologies (Nasdaq: NANX ) ... products, announced today that the Company accepted the resignation ... Chief Technology Officer, so that he may pursue new ... several of the Company,s key patents and served as ...
... 3 WXYZ is proud to announce that ... Peter Nielsen , will now be seen exclusively on Channel ... than 15 years Peter Nielsen has hosted the nationally syndicated ... the author of numerous books and videos on health and fitness and ...
... the day has surprising impact on young people GAITHERSBURG, ... the importance of breakfast for students, Sodexo, a leading ... 470 school districts across the country, has created a ... time for National School Breakfast Week, March 2-6."Studies repeatedly ...
... to Improve, Automate Health Care in Master-Planned CommunitiesSCOTTSDALE, Ariz., ... of acres across the West but it,s his company,s ... would radically alter the use of energy grids. ... that message this week to The Wall Street Journal,s ...
... Exhibit www.donaldverger.com PORTLAND, Maine, March 3 A ... jail over a period of three days at ... the charges were dismissed, Verger was compelled to ... http://www.newscom.com/cgi-bin/prnh/20090303/NE78221 )"We are deeply grateful to Mr. ...
... of Pennsylvania School of Medicine and the University ... cells that spur misplaced bone growth. Unexpectedly, the ... vessels deep within skeletal muscle and other connective ... work also shows that cells important in the ...
Cached Medicine News:Health News:Nanophase Announces Changes in Principal Officers and Directors 2Health News:Nanophase Announces Changes in Principal Officers and Directors 3Health News:Peter Nielsen Has a New Home on WXYZ-TV! 2Health News:Sodexo Shares Top Breakfast Benefits for Students 2Health News:Innovative Plans by Major Arizona-Based Developer Sparks Landmark Energy Conservation Legislation in Multiple States to Urge Federal Action at Wall Street Journal Conference This Week with Gore, Google CEO & T. Boone Pickens 2Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 2Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 3Health News:Award Winning Photographer and Museum Founder to Donate Iconic Images In Support of the Innocence Project 4Health News:Misplaced metamorphosis 2
... innovative B-Twin Expandable Spinal System is intended ... The Implant - preloaded on its Delivery ... intervertebral space in a reduced configuration of ... up to 15mm (depending on the size ...
... on the Alpha 5 include a newly ... digital processor specifically designed for ultrasonic signals. ... reduces image speckle and enables clearer imaging ... The enhanced user confidence afforded by Alpha ...
... NCP-2, ACS proudly introduces full disclosure to ... tools for assessing the administration of ECP ... ECP Treatment Report.,The ACS Treatment Report is ... both physicians and therapists to review patient ...
... monitors and controls patient temperature primarily in ... surgery, trauma, or other medical conditions. The ... provided from a patient temperature probe. Circulating ... and 42C (107.6F) to achieve a preset ...
Medicine Products: